Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matus Rehak

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Thrombosis and Haemostasis|May 2, 2008
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysisMatus Rehak, Jiri Rehak, Marc Müller, et al.
American Journal of Ophthalmology|July 3, 2015
Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and OutcomeIra Seibel, Dino Cordini, Matus Rehak, et al.
Magnetic Resonance in Medicine|November 17, 2016
Magnetic resonance safety and compatibility of tantalum markers used in proton beam therapy for intraocular tumors: A 7.0 Tesla studyEva Oberacker, Katharina Paul, Till Huelnhagen, et al.
Current Eye Research|November 1, 2019
Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: <i>Post-hoc</i> Analysis from the COMRADE TrialsAmelie Pielen, Nicolas Feltgen, Lars-Olof Hattenbach, et al.
Acta Diabetologica|May 16, 2019
TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDYMatias Iglicki, Dinah Zur, Adrian Fung, et al.
Acta Ophthalmologica|June 2, 2018
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension studyNicolas Feltgen, Lars-Olof Hattenbach, Thomas Bertelmann, et al.
Cardiovascular and Interventional Radiology|October 30, 2021
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancersRhea Veelken, Bettina Maiwald, Steffen Strocka, et al.
Ophthalmology and Therapy|April 15, 2022
Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European CountriesSarah Lebrize, Louis Arnould, Abderrahmane Bourredjem, et al.
Acta Ophthalmologica|March 3, 2017
Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, et al.
American Journal of Ophthalmology|May 11, 2016
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label StudyHans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Thrombosis and Haemostasis|May 2, 2008
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysisMatus Rehak, Jiri Rehak, Marc Müller, et al.
American Journal of Ophthalmology|July 3, 2015
Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and OutcomeIra Seibel, Dino Cordini, Matus Rehak, et al.
Magnetic Resonance in Medicine|November 17, 2016
Magnetic resonance safety and compatibility of tantalum markers used in proton beam therapy for intraocular tumors: A 7.0 Tesla studyEva Oberacker, Katharina Paul, Till Huelnhagen, et al.
Current Eye Research|November 1, 2019
Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: <i>Post-hoc</i> Analysis from the COMRADE TrialsAmelie Pielen, Nicolas Feltgen, Lars-Olof Hattenbach, et al.
Acta Diabetologica|May 16, 2019
TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDYMatias Iglicki, Dinah Zur, Adrian Fung, et al.
Acta Ophthalmologica|June 2, 2018
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension studyNicolas Feltgen, Lars-Olof Hattenbach, Thomas Bertelmann, et al.
Cardiovascular and Interventional Radiology|October 30, 2021
Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancersRhea Veelken, Bettina Maiwald, Steffen Strocka, et al.
Ophthalmology and Therapy|April 15, 2022
Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European CountriesSarah Lebrize, Louis Arnould, Abderrahmane Bourredjem, et al.
Acta Ophthalmologica|March 3, 2017
Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)Lars-Olof Hattenbach, Nicolas Feltgen, Thomas Bertelmann, et al.
American Journal of Ophthalmology|May 11, 2016
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label StudyHans Hoerauf, Nicolas Feltgen, Claudia Weiss, et al.
Pageof 10